Compare TLPH & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLPH | LITS |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 41.5M |
| IPO Year | 2010 | N/A |
| Metric | TLPH | LITS |
|---|---|---|
| Price | $0.77 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 168.3K | ★ 232.5K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.95 |
| 52 Week High | $1.57 | $3.03 |
| Indicator | TLPH | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 54.03 |
| Support Level | $0.73 | $1.17 |
| Resistance Level | $0.79 | $1.26 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 49.48 | 83.33 |
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.